New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
07:17 EDTCYCCCyclacel Pharmaceuticals issued new Japanese patent
Cyclacel Pharmaceuticals announced that the Japanese Patent and Trademark Office issued two patents broadening the exclusivity of sapacitabine, the company's lead clinical candidate. Japanese Patent 5443763 claims novel pharmaceutical formulations of sapacitabine. Japanese Patent 5457196 claims methods of treating cancer comprising sapacitabine in combination with histone deacetylase inhibitors. Equivalent patents have been granted in the United States and other countries.
News For CYCC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 12, 2015
16:12 EDTCYCCCyclacel Pharmaceuticals reports Q1 EPS (19c), one estimate (25c)
Reports Q1 revenue $512,000 vs. $396,000 last year. "Approximately 20% of the prespecified events remain to be observed before we unblind SEAMLESS, our pivotal, Phase 3 study of sapacitabine in patients aged 70 years or older with acute myeloid leukemia (AML) who are unfit or have refused intensive chemotherapy. We expect this to occur between the second half of 2015 and the first half of 2016. As we continue study follow-up, we have begun preparations for submission of a Pediatric Investigation Plan to the European Medicines Agency. In parallel with sapacitabine activities, we are progressing development of CYC065, our novel, second-generation cyclin dependent kinase 2/9 inhibitor. Following submission of our Investigational New Drug application, we have received clearance from the FDA to begin a first-in-human, Phase 1 clinical trial of CYC065, which will commence following institutional review board approval. We have cash resources for the next two years which are sufficient to advance these programs and deliver on our key milestones," said CEO Spiro Rombotis.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use